H. Lundbeck A/S

9 Ottiliavej DK-2500 Valby
Copenhagen Denmark

Tel +45 36 30 13 11
Fax +45 36 30 19 40

E-mail information@lundbeck.com
www.lundbeck.com

Release No 34

15 November 2000

Lundbeck's compound for the treatment of insomnia - gaboxadol - enters clinical phase II

H. Lundbeck A/S hereby announces that gaboxadol has initiated the first clinical phase II study. Gaboxadol (a selective $GABA_A$ receptor agonist) is a compound for the treatment of insomnia.

Insomnia is extremely common. Various epidemiological sources estimate that the prevalence of insomnia is approximately 19-36% of the adult population and can be associated with the development of a number of somatic and mental illnesses. It is estimated that 25-35% of all insomniacs has a co-morbid psychiatric disorder or a drug or alcohol abuse. Approximately 37% self-medicate with OTC treatment and 16% use alcohol.

Currently available agents for treatment of insomnia, like benzodiazepines, induce an abnormal sleep pattern, as verified by electroencephalographic (EEG) records. This includes suppression of deep sleep and rapid eye movement (REM) sleep. In addition, these agents affect EEG during wakefulness, reflecting a weakening of mental performance.

The unmet needs of the market are hypnotics that do not impair the sleep quality, and are suitable for long-term treatment without producing tolerance and withdrawal symptoms.

Explorative studies in young and elderly have demonstrated that gaboxadol is able to increase sleep continuity and sleep intensity without suppressing REM sleep. Consequently, gaboxadol might have therapeutic prospects in the treatment of insomnia characterised by frequent awakenings and reduced sleep quality.

The content of this release will not influence the Lundbeck Group's expectations for the financial result 2000.

For further information please contact Hans Henrik Munch-Jensen, CFO, phone +45 36 30 15 11, ext. 2660.

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological diseases. It had consolidated net turnover of DKK 4.2 billion in 1999 and employs approximately 3,000 people.